Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen

Fig. 6

Whole tumor Ag-loaded natural cDC1s reduce progression of anti-PD-1 susceptible MC38 tumors, potentiating anti-PD-1 therapy. a Schematic representation of treatment and analysis. Mice grafted subcutaneously with 106 MC38 cancer cells (day 0) were intradermally injected with PBS (Control and αPD-1-treated groups) or 106 poly I:C and autologous MC38 TCL-loaded cDC1s (cDC1s- and cDC1s + αPD-1-treated groups) at day 6 & 13 days as well as intraperitoneally injected with PBS (Control and cDC1s-treated groups) or 100 μg anti-PD-1 antibody (αPD-1- and cDC1s + αPD-1-treated groups) on days 7, 10, 14 & 17 and tumor progression monitored. b Representative images of tumors on day 20, c tumor growth, d detailed statistics of tumor size at individual days and e survival curve before reaching the humane endpoint of mice treated as described in (a). Remaining, surviving mice in (e) completely rejected the tumor and were followed for at least 3 months. White dashed lines in (b) indicate tumor margin. Combined data of 2 independent experiments with total n = 18 (Control, αPD-1 and cDC1s + αPD-1-treated groups) and n = 19 (cDC1s-treated group) mice are shown. *P < 0.05, **P < 0.01, ***P < 0.001 by c Two-Way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001 by d Student’s t test, *P < 0.05, ***P < 0.001 by e Mantel-Cox test, ns: not significant

Back to article page